CF transmembrane conductance regulator
Last updated 3 Apr 2025
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The CFTR gene provides instructions for making a protein called the CF transmembrane conductance regulator (CFTR). This protein functions as a channel across the membrane of cells that produce mucus, sweat, saliva, tears, and digestive enzymes. The channel transports negatively charged particles called chloride ions into and out of cells. The transport of chloride ions helps control the movement of water in tissues, which is necessary for the production of thin, freely flowing mucus. Mucus is a slippery substance that lubricates and protects the lining of the airways, digestive system, reproductive system, and other organs and tissues.
Video picks for GenesVideo library
Normal function
The CFTR gene provides instructions for making a protein called the CF transmembrane conductance regulator (CFTR). This protein functions as a channel across the membrane of cells that produce mucus, sweat, saliva, tears, and digestive enzymes. The channel transports negatively charged particles called chloride ions into and out of cells. The transport of chloride ions helps control the movement of water in tissues, which is necessary for the production of thin, freely flowing mucus. Mucus is a slippery substance that lubricates and protects the lining of the airways, digestive system, reproductive system, and other organs and tissues.
The CFTR protein also regulates the function of other channels, such as those that transport positively charged particles called sodium ions across cell membranes. These channels are necessary for the normal function of organs such as the lungs and pancreas.
Conditions referring to this gene or chromosome
Other names
ABC35
ABCC7
cAMP-dependent chloride channel
CF
CFTR_HUMAN
cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)
cystic fibrosis transmembrane conductance regulator, ATP-binding cassette (sub-family C, member 7)
MRP7
Patient picks for Genes

Health news
Influencers are promoting dangerous peptides on social media – and regulators are struggling to keep up
Once confined to niche bodybuilding forums and hardcore gyms, unproven injectable peptides are now being openly marketed online to the average gym-goer by social media influencers – and regulators struggling to keep up. Across Instagram, TikTok or YouTube, unapproved and harmful peptide products are being promoted as shortcuts to fat loss, anti-ageing, health and recovery and muscle growth. Peptides actually occur naturally in our body. They regulate a variety of important functions, including metabolism, appetite, hormone production and tissue repair. Synthetic versions of peptides are also used in some medicines, which are legitimate and have been clinically proven. These include GLP-1s (which are used for weight loss and managing diabetes) and insulin. But a booming, parallel “grey market” now exists online for unapproved peptide compounds. These products are primarily being sold by so-called wellness brands and in influencer-led storefronts. Many of these products are marketed as cutting-edge solutions for optimising health and body enhancement. The problem is that many of these substances have not undergone full clinical safety evaluation and are not approved for human use. Many have also been found to be contaminated with other harmful ingredients. Unapproved injectable peptides therefore pose serious health risks. Some of the risks they may pose00092-0/abstract) include nausea, vomiting, abdominal pain, gastrointestinal issues, headaches and fatigue or weakness. Immune issues, as well as allergic reactions and infections have also been reported. Moreover, there’s a clear lack of rigorous human safety data. Yet these risks often aren’t disclosed by the people selling them.
by Luke Cox

COVID-19
Why is ME/CFS research key to understanding long COVID?
A large number of people with long COVID are reporting similar symptoms to those who have myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Scientists are now researching the similarities between the two conditions. Many hope that exploring this interconnection will result in a better understanding of both long COVID and ME/CFS.
by Amberley Davis
Related patient information and medicines

Patient information leaflet
Newborn bloodspot test
Conditions wh... Treatment started early in life, can prevent complications. This may include taking regular antibiotics and having extra vaccinations. Cystic fibrosis Cystic fibrosis (CF) - this is an inherited disorder that affects the internal organs, especially the lungs and digestive system. The heel prick test detects a chemical called.

Patient information leaflet
Medical negligence
This leaflet will discuss these different options in more detail. How can you make a complaint about your treatment. There are several differ... There is a separate Health Service Ombudsman for England, Scotland, Wales and Northern Ireland. Governing bodies for health professionals Healthcare professionals are regulated by governing bodies, which.

Patient information leaflet
Astigmatism
Astigmatism is a common eye condition that affects the shape of the cornea or the lens of the eye. The cornea and lens are typically smooth and round in shape, but in people with astigmatism, they are irregularly shaped. The main symptom of astigmatism is blurred vision. It occurs because the cornea at the front of the eye is unevenly curved..

Patient information leaflet
Myopia
What is myopia (short-sightedness). Myopia (also known as short-sightedness or near-sightedness) is a refractive error that occurs when light coming from distant objects is 'overfocused', so that the point of focus is in front of the retina. It occurs because either the eyeball is too long or, less commonly, because the cornea is too curved..
Further reading and references
- CF transmembrane conductance regulator; MedlinePlus, National Library of Medicine.
- Cohn JA. Reduced CFTR function and the pathobiology of idiopathic pancreatitis. J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S70-7. doi: 10.1097/01.mcg.0000155522.89005.bf.
- Cuppens H, Cassiman JJ. CFTR mutations and polymorphisms in male infertility. Int J Androl. 2004 Oct;27(5):251-6. doi: 10.1111/j.1365-2605.2004.00485.x.
- Deignan JL, Astbury C, Cutting GR, Del Gaudio D, Gregg AR, Grody WW, Monaghan KG, Richards S; ACMG Laboratory Quality Assurance Committee. CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020 Aug;22(8):1288-1295. doi: 10.1038/s41436-020-0822-5. Epub 2020 May 14.
- Gadsby DC, Vergani P, Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature. 2006 Mar 23;440(7083):477-83. doi: 10.1038/nature04712.
- Kulczycki LL, Kostuch M, Bellanti JA. A clinical perspective of cystic fibrosis and new genetic findings: relationship of CFTR mutations to genotype-phenotype manifestations. Am J Med Genet A. 2003 Jan 30;116A(3):262-7. doi: 10.1002/ajmg.a.10886.
- Nick JA, Rodman DM. Manifestations of cystic fibrosis diagnosed in adulthood. Curr Opin Pulm Med. 2005 Nov;11(6):513-8. doi: 10.1097/01.mcp.0000183052.56728.76.
- Noone PG, Knowles MR. 'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res. 2001;2(6):328-32. doi: 10.1186/rr82. Epub 2001 Aug 9.
- Ratbi I, Legendre M, Niel F, Martin J, Soufir JC, Izard V, Costes B, Costa C, Goossens M, Girodon E. Detection of cystic fibrosis transmembrane conductance regulator (CFTR) gene rearrangements enriches the mutation spectrum in congenital bilateral absence of the vas deferens and impacts on genetic counselling. Hum Reprod. 2007 May;22(5):1285-91. doi: 10.1093/humrep/dem024. Epub 2007 Feb 28.
- Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005 May 12;352(19):1992-2001. doi: 10.1056/NEJMra043184. No abstract available.
- Savant A, Bojanowski CM, Upadia J. Cystic Fibrosis. 2001 Mar 26 [updated 2026 Oct 1]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1250/
- Taulan M, Girardet A, Guittard C, Altieri JP, Templin C, Beroud C, des Georges M, Claustres M. Large genomic rearrangements in the CFTR gene contribute to CBAVD. BMC Med Genet. 2007 Apr 20;8:22. doi: 10.1186/1471-2350-8-22.
- Vankeerberghen A, Cuppens H, Cassiman JJ. The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions. J Cyst Fibros. 2002 Mar;1(1):13-29. doi: 10.1016/s1569-1993(01)00003-0.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

